Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean
08/10/2026 09:02
BRIEF-Ono Pharmaceutical Co., Ltd.- Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean Oct 8 (Reuters) - ONO PHARMACEUTICAL CO., LTD. 4528.T:
ONO PHARMACEUTICAL CO., LTD.: ONO PHARMA ANNOUNCES AN EXCLUSIVE LICENSE AGREEMENT WITH BIOHAVEN TO DEVELOP AND COMMERCIALIZE IGG DEGRADERS IN JAPAN, SOUTH KOREA, TAIWAN, AND ASEAN
ONO PHARMACEUTICAL CO., LTD.: WILL PAY BIOHAVEN $80 MILLION AS AN UPFRONT PAYMENT AND $20 MILLION AS A MILESTONE ACHIEVEMENT PAYMENT, AND ROYALTIES OF APPROXIMATELY 20% ON NET SALES
Source text: ID:nTSvh85c7e
Further company coverage: 4528.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on ONO PHARMACEUTICAL
See all newsBrief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean
Bristol Myers sues Amgen over proposed Opdivo biosimilar (updated)
Bristol Myers sues Amgen over proposed Opdivo biosimilar
Brief: UK's MHRA Says Vimseltinib Approved For Use In Adults To Treat Tenosynovial Giant Cell Tumours